It is therefore an apt description for the Ebola clinical trial now underway which is testing the safety and tolerability of SNALP LNP delivery following multiple consecutive daily administrations. This compares to once-weekly and once-a-monthly regimens tested so far. If SNALP LNP comes out positive from this, it would provide great comfort around the safety and tolerability of the industry’s most potent delivery technology for gene knockdown in the liver, in addition to paving the way towards more biodefense applications.
Tuesday, March 4, 2014
The Ebola Clinical Trial a Real ‘Haertetest’ for SNALP LNP Delivery
It is therefore an apt description for the Ebola clinical trial now underway which is testing the safety and tolerability of SNALP LNP delivery following multiple consecutive daily administrations. This compares to once-weekly and once-a-monthly regimens tested so far. If SNALP LNP comes out positive from this, it would provide great comfort around the safety and tolerability of the industry’s most potent delivery technology for gene knockdown in the liver, in addition to paving the way towards more biodefense applications.
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.
4 comments:
The CT sites shows results expected by July 2014. Do you expect any info before then? Also, when looking at the CT site, that's a quite extensive inclusion/exclusion list. Compare that to the ALN-TTRsc list for example. Is there anything to be read into that?
Steve
Inclusion/exclusion criteria what expected for 'healthy' volunteer trial. Taking out confounding variables such as alcohol consumption will facilitate interpretation of trial results.
Is there a connection between TKMRs shelf and the one RGLS filed today? Common thread being mRNA and ALNY. ALNY closed their partnership out with GENZ the other day. Wonder if ALNY, GENZ or someone else is about to take a stake in TKMR and RGLS.
ExperiencedMentor's bigger fish pic looms large.
Hello, thanks for the great article!
Post a Comment